Suppr超能文献

尿皮质素 II 受体在结肠癌细胞系和人类结肠癌中过度表达。

Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans.

机构信息

Gastroenterology Unit, Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy.

出版信息

Eur J Clin Invest. 2014;44(3):285-94. doi: 10.1111/eci.12231. Epub 2014 Jan 22.

Abstract

BACKGROUND

Urotensin (U)-II receptor (UTR) has been previously reported to be over-expressed in a number of tumours. Whether UTR-related pathway plays a role in colon carcinogenesis is unknown.

METHODS

We evaluated UTR protein and mRNA expression in human epithelial colon cancer cell lines and in normal colon tissue, adenomatous polyps and colon cancer. U-II protein expression was assessed in cancer cell lines. Moreover, we evaluated the effects of U-II(4-11) (an UTR agonist), antagonists and knockdown of UTR protein expression through a specific shRNA, on proliferation, invasion and motility of human colon cancer cells.

RESULTS

Cancer cell lines expressed U-II protein and UTR protein and mRNA. By immunohistochemistry, UTR was expressed in 5-30% of epithelial cells in 45 normal controls, in 30-48% in 21 adenomatous polyps and in 65-90% in 48 colon adenocarcinomas. UTR mRNA expression was increased by threefold in adenomatous polyps and eightfold in colon cancer, compared with normal colon. U-II(4-11) induced a 20-40% increase in cell growth while the blockade of the receptor with specific antagonists caused growth inhibition of 20-40%. Moreover, the knock down of UTR with a shRNA or the inhibition of UTR with the antagonist urantide induced an approximately 50% inhibition of both motility and invasion.

CONCLUSIONS

UTR appears to be involved in the regulation of colon cancer cell invasion and motility. These data suggest that UTR-related pathway may play a role in colon carcinogenesis and that UTR may function as a target for therapeutic intervention in colon cancer.

摘要

背景

先前已有报道称,尾加压素(U)-II 受体(UTR)在许多肿瘤中过度表达。UTR 相关途径是否在结肠癌变中起作用尚不清楚。

方法

我们评估了人上皮结肠癌细胞系和正常结肠组织、腺瘤性息肉和结肠癌中 UTR 蛋白和 mRNA 的表达。评估了癌症细胞系中 U-II 蛋白的表达。此外,我们还评估了 U-II(4-11)(UTR 激动剂)、拮抗剂和通过特异性 shRNA 降低 UTR 蛋白表达对人结肠癌细胞增殖、侵袭和迁移的影响。

结果

癌细胞系表达 U-II 蛋白和 UTR 蛋白和 mRNA。通过免疫组织化学染色,在 45 例正常对照中,UTR 在 5-30%的上皮细胞中表达,在 21 例腺瘤性息肉中在 30-48%的上皮细胞中表达,在 48 例结肠腺癌中在 65-90%的上皮细胞中表达。与正常结肠相比,腺瘤性息肉中 UTR mRNA 表达增加了三倍,结肠腺癌中增加了八倍。UTR 激动剂 U-II(4-11)诱导细胞生长增加 20-40%,而特异性拮抗剂阻断受体导致细胞生长抑制 20-40%。此外,shRNA 敲低 UTR 或拮抗剂 urantide 抑制 UTR 可导致运动和侵袭性降低约 50%。

结论

UTR 似乎参与了结肠癌细胞侵袭和迁移的调节。这些数据表明,UTR 相关途径可能在结肠癌变中起作用,UTR 可能作为结肠癌治疗干预的靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验